Clinical Trials Logo

Clinical Trial Summary

The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.


Clinical Trial Description

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder, in which platelet surface GPIIb/IIIa and GPIb/IX are the two most frequently targeted autoantigens. Our previous studies in animal models of ITP demonstrated that intravenous immunoglobulin G (IVIG) could protect against anti-GPIIb/IIIa-mediated thrombocytopenia but failed to ameliorate ITP induced by most anti-GPIb/IX antibodies. The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment. ;


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT01666795
Study type Observational
Source Shandong University
Contact
Status Completed
Phase N/A
Start date February 2005
Completion date January 2014

See also
  Status Clinical Trial Phase
Completed NCT02868060 - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) Phase 1/Phase 2
Completed NCT04346654 - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP Phase 2
Not yet recruiting NCT06371417 - Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) Phase 1
Terminated NCT01054443 - A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) Phase 2
Recruiting NCT04915482 - TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2/Phase 3
Completed NCT00344149 - Rituximab as Second Line Treatment for ITP Phase 3
Completed NCT04669600 - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) Phase 2
Terminated NCT05086744 - Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders Phase 2
Recruiting NCT03951623 - The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients Phase 1
Recruiting NCT04968899 - IgIV Plus Prednisone vs High-dose Dexamethasone for ITP Phase 3
Recruiting NCT03975361 - Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE) N/A